Spots Global Cancer Trial Database for neuroendocrine tumors
Every month we try and update this database with for neuroendocrine tumors cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| 5FU and Octreotide Long-acting Release (LAR) for Neuroendocrine Tumors | NCT00953394 | Neuroendocrine ... | continuous 5 fl... | 18 Years - | University of Turin, Italy | |
| Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors | NCT01628913 | Pancreatic Neur... | BEZ235 Everolimus | 18 Years - | Novartis | |
| Beta- Probe and Surgery in GEP NET: Evaluation of a New Probe | NCT04296149 | Neuroendocrine ... | Y90-DOTA-Tyr3-O... | 18 Years - | European Institute of Oncology | |
| Nonfunctioning Small (≤2 cm) Neuroendocrine Pancreatic Incidentaloma | NCT03022188 | Neuroendocrine ... | 18 Years - | Société Française d'Endoscopie Digestive | ||
| Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours. | NCT01398306 | Carcinoma Carcinoma, Rena... Neuroendocrine ... Carcinoid Tumor Pancreatic Isle... | Blood sampling ... | 18 Years - | University Medical Center Groningen | |
| Early Identification of Cardiac Involvement in Patients With Carcinoid: Clinical and Prognostic Implications | NCT06321692 | Neuroendocrine ... | Evaluation of b... | 18 Years - | European Institute of Oncology | |
| 68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs) | NCT02359500 | Neuroendocrine ... Carcinoid Tumor... | 68Ga-DOTATOC PE... | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors | NCT00137774 | Neuroendocrine ... | Bevacizumab Temozolomide | 18 Years - | Dana-Farber Cancer Institute | |
| 68Ga-DOTA-MGS5 PET/CT in Patients With Advanced Neuroendocrine Tumours | NCT06155994 | Neuroendocrine ... | 68Ga-DOTA-MGS5 | 18 Years - | Medical University Innsbruck | |
| Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor | NCT01175096 | Neuroendocrine ... Carcinoid Tumor | RAD001 (everoli... | 18 Years - | Guangdong Provincial People's Hospital | |
| Financial Toxicity and Patient-Reported Outcomes in GEP-NEN During Treatment | NCT05334290 | Neuroendocrine ... | 18 Years - | IRCCS San Raffaele | ||
| Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | NCT02568267 | Breast Cancer Cholangiocarcin... Colorectal Canc... Head and Neck N... Lymphoma, Large... Melanoma Neuroendocrine ... Non-Small Cell ... Ovarian Cancer Pancreatic Canc... Papillary Thyro... Primary Brain T... Renal Cell Carc... Sarcomas Salivary Gland ... Adult Solid Tum... | Entrectinib | 18 Years - | Hoffmann-La Roche | |
| A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements | NCT03093116 | Locally Advance... Metastatic Soli... | Oral repotrecti... | 12 Years - | Turning Point Therapeutics, Inc. | |
| Study to Assess the Use of Lanreotide Autogel® 120 mg in Patients With Locally Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) in Routine Clinical Practice | NCT03895463 | Neuroendocrine ... | 18 Years - | Ipsen | ||
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | NCT03452774 | Cancer, Metasta... Cancer Cancer of Pancr... Cancer of Liver Cancer of Stoma... Cancer Liver Cancer of Rectu... Cancer of Kidne... Cancer of Esoph... Cancer of Cervi... Cancer of Colon Cancer of Laryn... Cancer, Lung Cancer, Breast Cancer, Advance... Cancer Prostate Cancer of Neck Cancer of Skin Neuroendocrine ... Carcinoma Mismatch Repair... BRCA Gene Rearr... Non Hodgkin Lym... Leukemia Non Small Cell ... Cholangiocarcin... Glioblastoma Central Nervous... Melanoma Urothelial Carc... Bladder Cancer Ovarian Cancer Endometrial Can... Testicular Canc... Breast Cancer COVID Myelofibrosis Myeloproliferat... Myeloproliferat... Follicular Lymp... Mantle Cell Lym... Marginal Zone L... Myelodysplastic... | Clinical Trial ... | - | Massive Bio, Inc. | |
| A Real-world Comparison of FNB and FNA in IHC-required Lesions. | NCT05565066 | Neuroendocrine ... Autoimmune Panc... Gastrointestina... | FNB group FNA group | 18 Years - | Huazhong University of Science and Technology | |
| Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer | NCT02174549 | Hepatocellular ... Gastrointestina... Neuroendocrine ... | Tirapazamine Conventional Tr... | 20 Years - 99 Years | Teclison Ltd. | |
| Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies | NCT01794793 | Cushing's Disea... Acromegaly Neuroendocrine ... Pituitary Tumor... Ectopic ACTH Se... Dumping Syndrom... Prostate Cancer Melanoma Negati... Melanoma Negati... | Pasireotide Cabergoline Pasireotide | 18 Years - | RECORDATI GROUP | |
| Systemic Therapy With or Without Upfront Transarterial Embolization for Inoperable Liver Metastasis of Neuroendocrine Tumors | NCT01755182 | Neuroendocrine ... | approved pharma... TAE | 18 Years - 80 Years | National Cancer Institute, Naples | |
| Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department | NCT04104529 | Thyroid Cancer Prostate Cancer Neuroendocrine ... | Biological coll... tumor collectio... | 18 Years - | Institut du Cancer de Montpellier - Val d'Aurelle | |
| Resection of Metastatic Pancreatic Neuroendocrine Tumors After Induction System Treatment | NCT04066322 | Neuroendocrine ... Metastases Surgery | system treatmen... system treatmen... | 18 Years - 80 Years | Fudan University | |
| Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms | NCT05709171 | GEP-NET Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... | 18F-FDG 64Cu-Dotatate | 18 Years - | Rigshospitalet, Denmark | |
| A Study of Etoposide-carboplatin in Combination With Pembrolizumab and Lenvatinib Maintenance in HG-NETs | NCT06232564 | Neuroendocrine ... | Pembrolizumab i... | 18 Years - | Imperial College London | |
| Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors | NCT02743741 | Neuroendocrine ... | Lutetium-177 Oc... | - | University Health Network, Toronto | |
| Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors | NCT05636618 | Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... Carcinoid Tumor... Carcinoid Tumor Paraganglioma Pheochromocytom... | [212Pb]VMT-α-NE... [212Pb]VMT-α-NE... | 18 Years - 90 Years | Perspective Therapeutics | |
| Neoadjuvant PRRT With 177Lu-DOTATATE Followed by Surgery for Resectable PanNET | NCT04385992 | Neuroendocrine ... | 177Lu-Dotatate | 18 Years - | IRCCS San Raffaele | |
| A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer | NCT00781911 | Carcinoma Neuroendocrine ... | Cixutumumab depot octreotid... | 18 Years - | Eli Lilly and Company | |
| Lipiodol Deposition Using Endhole vs. Pressure-Modulated Delivery | NCT06204159 | Hepatocellular ... Neuroendocrine ... | TACE Catheters | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Financial Toxicity and Patient-Reported Outcomes in GEP-NEN During Treatment | NCT05334290 | Neuroendocrine ... | 18 Years - | IRCCS San Raffaele | ||
| 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs | NCT04915144 | Neuroendocrine ... Carcinoid Tumor Pulmonary Carci... Gastroenteropan... Vipoma Insulinoma Gastrinoma | 177Lu-DOTATOC | 19 Years - | British Columbia Cancer Agency | |
| Post-Authorization Long-Term Safety Study of LUTATHERA | NCT03691064 | Neuroendocrine ... | LUTATHERA | 18 Years - | Advanced Accelerator Applications | |
| Iconographic Registry of Pancreatobiliary Endoscopy Procedures | NCT06344507 | Pancreas Neopla... Cancer of Pancr... Pancreatitis Neuroendocrine ... | 18 Years - | IRCCS San Raffaele | ||
| Proton Boost for Locally Advanced HEAD AND NECK TUMORS | NCT03183271 | Epithelial Tumo... Neuroendocrine ... | external beam p... | 18 Years - 75 Years | CNAO National Center of Oncological Hadrontherapy | |
| Comparing Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases | NCT05987176 | Neuroendocrine ... | Lutathera | 18 Years - | Imperial College London | |
| Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas | NCT01744249 | Neuroendocrine ... Advanced Cancer | Axitinib Sandostatin LAR Placebo | 18 Years - | Grupo Espanol de Tumores Neuroendocrinos | |
| Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma | NCT00780663 | Neuroendocrine ... Carcinoid Tumor | Quarfloxin | 18 Years - | Cylene Pharmaceuticals | |
| Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET) | NCT01169649 | PANCREAS Neuroendocrine | MK-2206 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Gastroenteral-Pancreatic Neuroendocrine Tumors in Taiwan | NCT02102893 | Neuroendocrine ... | 20 Years - 75 Years | National Health Research Institutes, Taiwan | ||
| Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors | NCT04074135 | VHL Pancreatic ... Von Hippel-Lind... Neuroendocrine ... | 68-Gallium DOTA... | 12 Years - | National Institutes of Health Clinical Center (CC) | |
| "Receptor Radionuclide Therapy With 177Lu-DOTATOC | NCT06045260 | Neuroendocrine ... Paraganglioma Pheochromocytom... | 177Lu-DOTATOC | 18 Years - | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | |
| Efficacy of 177-Lu-DOTA 0, Tyr 3 Octreotate | NCT02125474 | Neuroendocrine ... | [177Lu] DOTA-TA... | 18 Years - 90 Years | Instituto Nacional de Cancerologia, Columbia | |
| Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas | NCT01744249 | Neuroendocrine ... Advanced Cancer | Axitinib Sandostatin LAR Placebo | 18 Years - | Grupo Espanol de Tumores Neuroendocrinos | |
| Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET) | NCT04086485 | Gastroenteropan... Neuroendocrine ... Neuroendocrine ... | Lu-177-DOTATATE Olaparib Ga dotatate sca... FDG-PET scannin... Amino Acid infu... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors | NCT00947167 | Neuroendocrine ... Carcinoid Tumor... Adrenal Gland T... Neuroblastoma Pancreatic Neur... Multiple Endocr... | pertuzumab erlotinib | - | Stanford University | |
| TheraSphere Selective Internal Radiation Therapy (SIRT) as Treatment for Neuroendocrine Tumours With Liver Mets | NCT04362436 | Neuroendocrine ... Liver Metastase... | TheraSpheres Se... | 18 Years - | Imperial College London | |
| The Patient's Journey - the Time to Final Diagnosis in Patients With SiNET | NCT03840720 | Neuroendocrine ... | 18 Years - | Vastra Gotaland Region | ||
| Study of the Value of hPG80 (Circulating Progastrin) for the Diagnosis of Neuroendocrine Tumours in Patients With an MEN1 Mutation | NCT06430021 | Neuroendocrine ... MEN1 Mutation | blood sample | 18 Years - 60 Years | Centre Hospitalier Universitaire Dijon | |
| TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors | NCT03079440 | Neuroendocrine ... Neuroendocrine ... Temozolomide Capecitabine | TEMCAP | 19 Years - | Asan Medical Center | |
| Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors | NCT03335670 | Neuroendocrine ... | [68Ga]Pentixafo... | 18 Years - | University of Iowa | |
| Personalized PRRT of Neuroendocrine Tumors | NCT02754297 | Neuroendocrine ... Carcinoid Tumor Carcinoma, Neur... | 177Lu-Octreotat... | 18 Years - | CHU de Quebec-Universite Laval | |
| A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors | NCT00947167 | Neuroendocrine ... Carcinoid Tumor... Adrenal Gland T... Neuroblastoma Pancreatic Neur... Multiple Endocr... | pertuzumab erlotinib | - | Stanford University | |
| Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors | NCT04889742 | Recurrent Cance... Prostate Cancer Cervical Cancer Anal Cancer Sarcoma Rectal Cancer Neuroendocrine ... Esophageal Canc... Pancreas Cancer Squamous Cell C... | loco-regional h... | 18 Years - | Charite University, Berlin, Germany | |
| 68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors | NCT04888481 | Neuroendocrine ... | 68Ga-HA-DOTATAT... | - | University of Alberta | |
| Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers | NCT03935893 | Gastric Cancer Colorectal Canc... Pancreatic Canc... Sarcoma Mesothelioma Neuroendocrine ... Squamous Cell C... Merkel Cell Car... Mismatch Repair... Microsatellite ... | Tumor Infiltrat... Fludarabine + C... | 18 Years - 75 Years | University of Pittsburgh | |
| Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs) | NCT01253161 | Neuroendocrine ... Carcinoid Tumor... | Pasireotide Lon... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors | NCT03420521 | Neuroendocrine ... Carcinoid Tumor | Nivolumab Ipilimumab | 18 Years - 100 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Psychosocial Screening for Neuroendocrine Tumor Patients | NCT03372356 | Neuroendocrine ... | 18 Years - | Peking University | ||
| PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours | NCT05053854 | Neuroendocrine ... | Talazoparib | 18 Years - | Peter MacCallum Cancer Centre, Australia | |
| 68-Ga-labeled Octreotide Analogues PET in Duodenal-pancreatic Neuroendocrine Tumours | NCT01673906 | Neuroendocrine ... | Diagnostic work... | 18 Years - 90 Years | Arcispedale Santa Maria Nuova-IRCCS | |
| Pharmaco-immunological Study of Interferon-alpha and Metronomic Cyclophosphamide Association in Neuroendocrine Tumors | NCT02838342 | Neuroendocrine ... | Metronomic cycl... Interferon-alph... | 18 Years - | Centre Hospitalier Universitaire de Besancon | |
| A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies | NCT05199272 | Solid Tumor Clear Cell Rena... Epithelial Ovar... Fallopian Tube ... Primary Periton... Neuroendocrine ... MSI-H Cancer Cancer With A H... Extensive-stage... | 23ME-00610 | 12 Years - | 23andMe, Inc. | |
| A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors | NCT03070301 | Neuroendocrine ... | LEE011 everolimus | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| 5-HIAA in Urine Versus 5-HIAA in Plasma Patients With a Serotonin Producing Neuroendocrine Tumor' | NCT02507908 | Neuroendocrine ... | 18 Years - | University Medical Center Groningen | ||
| 89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine Tumors | NCT01338090 | Neuroendocrine ... | 89Zr-bevacizuma... Everolimus | 18 Years - 80 Years | University Medical Center Groningen | |
| EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx | NCT02705313 | Neuroendocrine ... | 177Lu-DOTA0-Tyr... | 18 Years - | Advanced Accelerator Applications | |
| Efficacy and Safety of 177Lu-Dotatate PRRT in Metastatic GEP-NEN Patients | NCT03422029 | Neuroendocrine ... | 177Lu-Dotatate ... | 18 Years - | Peking University | |
| Neuroendocrine Neoplasms Methylation Based Classifier - The NEMESIs-study | NCT05013957 | Neuroendocrine ... | Methylation ana... | 18 Years - 100 Years | University Hospital, Basel, Switzerland | |
| Neuroendocrine Tumors of Old Patients in the West of France | NCT03749681 | Neuroendocrine ... | 75 Years - | University Hospital, Brest | ||
| Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring | NCT05500391 | Stage I Testicu... Stage I Testicu... Gastrointestina... Ovarian Germ Ce... Adenocarcinoma,... Borderline Ovar... Sex Cord-Stroma... Mucinous Adenoc... Carcinoma, Smal... Carcinosarcoma,... Serous Tumor of... Glioma Neuroendocrine ... Aggressive Fibr... | Oncological Fol... | 18 Years - | Centre Oscar Lambret | |
| Neoadjuvant PRRT With 177Lu-DOTATATE Followed by Surgery for Resectable PanNET | NCT04385992 | Neuroendocrine ... | 177Lu-Dotatate | 18 Years - | IRCCS San Raffaele | |
| Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET. | NCT04276597 | Pulmonary Neuro... Pheochromocytom... Paraganglioma Thymus Carcinoi... Unknown Primary... Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... | 177Lu-DOTATOC | 18 Years - | Excel Diagnostics and Nuclear Oncology Center | |
| 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours | NCT04375267 | Clinical Trial,... Neuroendocrine ... Thymoma Mesothelioma | 177Lu-DOTA-TATE... | 18 Years - | Vastra Gotaland Region | |
| Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma | NCT04291885 | Merkel Cell Car... Merkel Cell Car... Merkel Cell Car... Merkel Cell Car... Neuroendocrine ... Carcinoma Neuro... | Avelumab Placebo | 18 Years - | Melanoma and Skin Cancer Trials Limited | |
| Natural History Study of Children and Adults With Neuroendocrine Neoplasms (NEN)s | NCT04488263 | Neuroendocrine ... Carcinoma, Neur... | 3 Years - | National Institutes of Health Clinical Center (CC) | ||
| Device Assisted Full Thickness Resection Versus Endoscopic Submucosal Dissection for Duodenal Neuroendocrine Tumors | NCT06121752 | Neuroendocrine ... | Endoscopic subm... EFTR | 18 Years - 80 Years | Asian Institute of Gastroenterology, India | |
| A Clinical Trial With a New Needle Device Comparing Two Needles for EUS_FNA of Solid Lesions. | NCT02246322 | Pancreatic Canc... Neuroendocrine ... Lymphadenopathi... GIST Gastric Wall Tu... | 25G needle 22G needle | 18 Years - | Istituto Clinico Humanitas | |
| Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET | NCT03083210 | Neuroendocrine ... | Lanreotide | 18 Years - | Samsung Medical Center | |
| Ki67 Proliferation Index of Pancreatic Neuroendocrine Neoplasia | NCT04753229 | Neuroendocrine ... | 18 Years - | Institut Paoli-Calmettes | ||
| EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer. | NCT06263088 | Gastrointestina... Colon Cancer Rectal Cancer Anal Cancer Esophageal Canc... Stomach Cancer Appendix Cancer Pancreas Cancer Liver Cancer Neuroendocrine ... | EQUITY GI | 18 Years - | Case Comprehensive Cancer Center | |
| Study of Recombinant Adenovirus AdVince in Patients With Neuroendocrine Tumors; Safety and Efficacy | NCT02749331 | Neuroendocrine ... | AdVince | 18 Years - 100 Years | Uppsala University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
